Literature DB >> 23913301

The role of dorsomedial and ventrolateral columns of the periaqueductal gray matter and in situ 5-HT₂A and 5-HT₂C serotonergic receptors in post-ictal antinociception.

Renato Leonardo de Freitas1, Rithiele Cristina de Oliveira, Ricardo de Oliveira, Tatiana Paschoalin-Maurin, Fernando Morgan de Aguiar Corrêa, Norberto Cysne Coimbra.   

Abstract

The periaqueductal gray matter (PAG) consists in a brainstem structure rich in 5-hydroxytryptamine (5-HT) inputs related to the modulation of pain. The involvement of each of the serotonergic receptor subtypes found in PAG columns, such as the dorsomedial (dmPAG) and the ventrolateral (vlPAG) columns, regarding post-ictal antinociception have not been elucidated. The present work investigated the participation of the dmPAG and vlPAG columns in seizure-induced antinociception. Specifically, we studied the involvement of serotonergic neurotransmission in these columns on antinociceptive responses that follow tonic-clonic epileptic reactions induced by pentylenetetrazole (PTZ), an ionophore GABA-mediated Cl(-) influx antagonist. Microinjections of cobalt chloride (1.0 mM CoCl2 /0.2 µL) into the dmPAG and vlPAG caused an intermittent local synaptic inhibition and decreased post-ictal antinociception that had been recorded at various time points after seizures. Pretreatments of the dmPAG or the vlPAG columns with the nonselective serotonergic receptors antagonist methysergide (5.0 µg/0.2 µL) or intramesencephalic microinjections of ketanserin (5.0 µg/0.2 µL), a serotonergic antagonist with more affinity to 5-HT2A/2C receptors, decreased tonic-clonic seizure-induced antinociception. Both dmPAG and vlPAG treatment with either the 5-HT2A receptor selective antagonist R-96544 (10 nM/0.2 µL), or the 5-HT2C receptors selective antagonist RS-102221 (0.15 µg/0.2 µL) also decrease post-ictal antinociception. These findings suggest that serotonergic neurotransmission, which recruits both 5-HT2A and 5-HT2C serotonergic receptors in dmPAG and vlPAG columns, plays a critical role in the elaboration of post-ictal antinociception.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  5-HT2A and 5-HT2C serotonergic receptors; GABA-A receptors; periaqueductal gray matter; postictal antinociception; tonic-clonic seizures

Mesh:

Substances:

Year:  2013        PMID: 23913301     DOI: 10.1002/syn.21697

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

Review 1.  Awareness and current knowledge of epilepsy.

Authors:  Asmat Ullah Khan; Muhammad Akram; Muhammad Daniyal; Naheed Akhter; Muhammad Riaz; Naheed Akhtar; Mohammad Ali Shariati; Fozia Anjum; Samreen Gul Khan; Abida Parveen; Saeed Ahmad
Journal:  Metab Brain Dis       Date:  2019-10-11       Impact factor: 3.584

Review 2.  Defensive and Emotional Behavior Modulation by Serotonin in the Periaqueductal Gray.

Authors:  Priscila Vázquez-León; Abraham Miranda-Páez; Kenji Valencia-Flores; Hugo Sánchez-Castillo
Journal:  Cell Mol Neurobiol       Date:  2022-07-28       Impact factor: 4.231

3.  Blockade of Cannabinoid CB1 Receptors in the Dorsal Periaqueductal Gray Unmasks the Antinociceptive Effect of Local Injections of Anandamide in Mice.

Authors:  Diego C Mascarenhas; Karina S Gomes; Tatiani Sorregotti; Ricardo L Nunes-de-Souza
Journal:  Front Pharmacol       Date:  2017-10-04       Impact factor: 5.810

Review 4.  The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System.

Authors:  Zhuo-Ying Tao; Pei-Xing Wang; Si-Qi Wei; Richard J Traub; Jin-Feng Li; Dong-Yuan Cao
Journal:  Neural Plast       Date:  2019-12-17       Impact factor: 3.599

5.  Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy-migraine comorbid rats.

Authors:  Long Wang; Lu-Lan Fu; Zi-Ru Deng; Juan Zhang; Mei-Dan Zu; Jun-Cang Wu; Yu Wang
Journal:  Brain Behav       Date:  2022-05-12       Impact factor: 3.405

6.  The brain signature of paracetamol in healthy volunteers: a double-blind randomized trial.

Authors:  Gisèle Pickering; Adrian Kastler; Nicolas Macian; Bruno Pereira; Romain Valabrègue; Stéphane Lehericy; Louis Boyer; Claude Dubray; Betty Jean
Journal:  Drug Des Devel Ther       Date:  2015-07-23       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.